Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update
August 02 2017 - 08:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage
biopharmaceutical company focused on providing systemic
administration of therapeutics to patients using our proprietary
Adhesive Dermally-Applied Microarray (ADAM) technology, today
announced that it will host a conference call and webcast to be
held on Thursday, August 10, 2017 at 4:30PM ET. At this time,
management will discuss results for the second quarter of 2017 and
provide an operational update for the remainder of the year. The
Company will announce its financial results for this period in a
press release to be issued prior to the call.
To access the live webcast, please visit the Investor Relations
page of the Zosano Pharma website at
http://ir.zosanopharma.com/events.cfm. Alternatively, you may
access the live conference call by dialing (844) 379-5311 (U.S.) or
(209) 905-5963 (international). The conference ID number is
63312637.
A replay will be available on the company’s website
approximately three hours after the call and available through
August 31, 2017.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical
company focused on providing systemic administration of
therapeutics to patients using our proprietary Adhesive
Dermally-Applied Microarray, or ADAM technology. The Company
recently announced positive results from our ZOTRIP study that
evaluated M207, which is our proprietary formulation of
zolmitriptan delivered via our ADAM technology, as an acute
treatment for migraine. Zosano is focused on developing
products where rapid administration of established molecules with
known safety and efficacy profiles provides an increased benefit to
patients, for markets where patients remain underserved by existing
therapies. The Company anticipates that many of its current and
future development programs may enable the Company to utilize a
regulatory pathway that would streamline clinical development and
accelerate the path towards commercialization. Learn more at
www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, sufficiency
of our capital resources and need for future funding and other
future events and expectations. Readers are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading “Risk Factors” in the
Company’s most recent annual report on Form 10-K. Although we
believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2023 to Mar 2024